Lactobacillus composition and use thereof in improving depression caused by antibiotics

Through the combination of Lactobacillus plantarum GMNL-141 strain, Lactobacillus rhamnosus GM-020 strain and Lactobacillus acidophilus GMNL-185 strain, the intestinal flora imbalance and depression caused by antibiotics were improved, and the depression caused by antibiotic use was solved. The disease problem has achieved the recovery of intestinal flora and the improvement of emotional stability.

CN115747090BActive Publication Date: 2024-11-26GENMONT BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111421350.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-09-06
Filing Date
2021-11-26
Publication Date
2024-11-26
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

The use of antibiotics may lead to imbalance of the intestinal microbiota, which in turn causes side effects of neuropsychiatric-related diseases such as depression. The prior art has not yet fully characterized the therapeutic effect of specific probiotics on central nervous system diseases.

Method used

Using the combination of Lactobacillus plantarum GMNL-141 strain, Lactobacillus rhamnosus GM-020 strain and Lactobacillus acidophilus GMNL-185 strain as Lactobacillus composition, the increase of Bifidella by improving the imbalance of the intestinal microbiota The abundance of the genus, reduce the abundance of Staphylococcus, regulate the metabolism of flavonoids, isoquinoline alkaloids and niacin in the intestine, increase the synthesis of short-chain fatty acids, and prepare to improve depression caused by antibiotics.

Benefits of technology

The Lactobacillus composition was shown to effectively improve the depressive behavior and intestinal flora imbalance caused by antibiotics in animal experiments, and its efficacy is better than a single probiotic strain, which can quickly restore the intestinal flora to a close-to-health state and improve emotional stability .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115747090B_ABST
    Figure CN115747090B_ABST
Patent Text Reader

Abstract

The present invention provides a lactobacillus composition and its use in improving depression caused by antibiotics, wherein the lactobacillus composition comprises Lactobacillus plantarum GMNL-141 strain, Lactobacillus rhamnosus GM-020 strain, Lactobacillus acidophilus GMNL-185 strain, or a combination thereof, which can effectively improve the imbalance of individual intestinal flora caused by antibiotics, help stabilize and improve the species richness of intestinal flora, and increase the synthesis of flavonoids and flavonols, the synthesis of isoquinoline alkaloids, the synthesis of nicotinate and nicotinamide, and the synthesis of short-chain fatty acids in the intestine that help stabilize mood, thereby effectively improving depression caused by antibiotics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a lactobacillus composition and its use in improving depression caused by antibiotics, and in particular to a lactobacillus composition comprising a Lactobacillus plantarum GMNL-141 strain, a Lactobacillus rhamnosus GM-020 strain, a Lactobacillus acidophilus GMNL-185 strain, or a combination thereof, and its use in improving depression caused by antibiotics. Background Art

[0002] Antibiotics are chemical substances that can inhibit bacterial growth or kill bacteria. They are the most commonly used drugs in clinical practice to treat and prevent bacterial infection-related diseases. However, many recent studies have pointed out that the use of antibiotics may disrupt the composition of the patient's intestinal microbiota, thereby causing individuals to develop side effects of neuropsychiatric diseases such as schizophrenia, autism, anxiety, and depression.

[0003] In past studies, it has been found that an individual's intestinal microbiota and its metabolites are related to maintaining the balance of the host's nervous, endocrine, and immune systems. Under the stimulation of stressors, the secretion of glucocorticoids, epinephrine, and norepinephrine by the hypothalamus-pituitary-adrenal axis may increase the expression and secretion of proinflammatory cytokines in immune cells, thereby disrupting the composition of an individual's intestinal microbiota and possibly leading to the development of anxiety or other neuropsychiatric-related diseases.

[0004] The exact relationship between different diseases and different gut microbiota is not yet known, and the exact effects of additional administration of specific microbiota on the gut and at the systemic level and on any specific type of disease have not yet been fully characterized, especially for central nervous system diseases.

[0005] In summary, in the field of probiotics-related technologies, new methods need to be found to effectively treat specific diseases, especially side effects such as depression caused by the high frequency of antibiotic use. Summary of the invention

[0006] To solve the aforementioned problems, one object of the present invention is to provide a Lactobacillus plantarum (L. plantarum) GMNL-141 strain for improving depression (Anxiety) caused by antibiotics, and its deposit number is NITE BP-03510.

[0007] Another object of the present invention is to provide a lactobacillus composition for improving depression caused by antibiotics, comprising the Lactobacillus plantarum GMNL-141 strain as described above.

[0008] In another embodiment of the present invention, the lactobacillus composition further comprises a Lactobacillus rhamnosus (L.rhamnosus) GM-020 strain, a Lactobacillus acidophilus (L.acidophilus) GMNL-185 strain, or a combination thereof; wherein the Lactobacillus rhamnosus GM-020 strain has a deposit number of CCTCC M203098, and the Lactobacillus acidophilus GMNL-185 strain has a deposit number of CCTCCM2017764.

[0009] Among them, the Lactobacillus rhamnosus (L. rhamnosus) GM-020 strain is disclosed in the patent with application number 200410030169.8 and authorization announcement number CN100396770C. The Lactobacillus acidophilus (L. acidophilus) GMNL-185 strain is disclosed in the patent with application number 201810666262.X and authorization announcement number CN110628660B.

[0010] In another embodiment of the present invention, the Lactobacillus plantarum GMNL-141 strain, the Lactobacillus rhamnosus GM-020 strain, and the Lactobacillus acidophilus GMNL-185 strain are mixed in a ratio of 1:1:1.

[0011] In another embodiment of the present invention, the Lactobacillus plantarum GMNL-141 strain, the Lactobacillus rhamnosus GM-020 strain, and the Lactobacillus acidophilus GMNL-185 strain are live bacteria or dead bacteria.

[0012] In yet another embodiment of the present invention, the antibiotic is Ampicillin.

[0013] Another object of the present invention is to provide a use of a Lactobacillus composition for preparing a pharmaceutical composition for improving depression caused by antibiotics, wherein the Lactobacillus composition is the Lactobacillus composition as described above.

[0014] In yet another embodiment of the present invention, the antibiotic is Ampicillin.

[0015] In another embodiment of the present invention, the Lactobacillus composition improves the imbalance of intestinal flora and / or the decrease in species richness of intestinal flora caused by antibiotics.

[0016] In another embodiment of the present invention, the Lactobacillus composition increases the abundance of Bifidobacterium and / or decreases the abundance of Staphylococcus in the intestinal flora.

[0017] In another embodiment of the present invention, the Lactobacillus composition increases the synthesis of flavonone and flavonol, the synthesis of isoquinoline alkaloid, and / or the synthesis of nicotinate and nicotinamide in the intestine.

[0018] In another embodiment of the present invention, the Lactobacillus composition increases the synthesis of short-chain fatty acids (SCFA) in the intestine.

[0019] In another embodiment of the present invention, the effective amount of the lactobacillus composition is at least 6.7 x 10 8 cfu / kg.

[0020] In another embodiment of the present invention, the pharmaceutical composition is a medicine.

[0021] In another embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, carrier and / or adjuvant.

[0022] In another embodiment of the present invention, the dosage form of the pharmaceutical composition is a spray gas, a solution, a semi-solid preparation, a solid preparation, a gelatin capsule, a soft capsule, a tablet, a pill, a syrup, a mouthful of lozenge, a tablet, a chewing gum, and / or a freeze-dried powder preparation.

[0023] The present invention uses animal experiments to screen the best probiotic strains, namely, the Lactobacillus rhamnosus GM-020 strain, the Lactobacillus plantarum GMNL-141 strain, and the Lactobacillus acidophilus GMNL-185 strain, for improving depression caused by antibiotics. The three probiotic strains are prepared into a composite formula of the probiotic composition of the present invention. Animal experiments confirm that the probiotic composition of the present invention, whether in low or high doses, can effectively improve individual depressive behavior caused by antibiotics, and its efficacy is better than that of using a single probiotic strain.

[0024] Furthermore, the probiotic composition of the present invention can improve the imbalance of individual intestinal flora caused by antibiotics, and help stabilize and enhance the species richness of the intestinal flora, especially increase the abundance of Bifidobacterium and reduce the abundance of Staphylococcus, so that the individual intestinal flora can quickly return to a state close to that of a healthy individual. In addition, the probiotic composition of the present invention can regulate the intestinal flora of an individual to increase the biosynthesis of flavonoids and flavonols that help stabilize mood, the biosynthesis of isoquinoline alkaloids, and the metabolism of nicotinate and nicotinamide in the intestine, and can also directly increase the synthesis of short-chain fatty acids in the intestine, thereby improving depression or depressive behavior caused by taking antibiotics in an individual.

[0025] The following will further illustrate the implementation mode of the present invention with the help of drawings. The following examples are used to illustrate the present invention, not to limit the scope of the present invention. Anyone skilled in the art can make some changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be determined by the scope of the attached patent application. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1A The test results of improving the decrease in the nesting amount of mice after tube feeding of the probiotic composition of the present invention. Among them, a means compared with NC, P<0.05; b means compared with Amp, P<0.05; c means compared with NC, P=0.06.

[0027] Figure 1B The test results of improving the decreased swimming survival ability of mice after tube feeding of the probiotic composition of the present invention. Among them, a means compared with NC, P<0.05; b means compared with Amp, P<0.05; d means compared with NC, P=0.08.

[0028] Figure 2A The operating unit table is to classify the bacterial flora of the negative control group and the positive control group mice by bacterial phylum after tube feeding of the probiotic composition of the present invention.

[0029] Figure 2B This is an operational unit table for classifying the intestinal flora of mice in the negative control group and the positive control group by bacterial genus after tube-feeding with the probiotic composition of the present invention.

[0030] Figure 3 This is the result of α-diversity analysis of the improvement of intestinal flora in mice after tube feeding of the probiotic composition of the present invention.

[0031] Figure 4 The LEfSe analysis results of the intestinal flora of mice after tube feeding of the probiotic composition of the present invention were compared with those of the negative control group and the positive control group.

[0032] Figure 5A for Figure 4 The abundance of Staphylococcus aureus in the mouse intestinal flora in the LEfSe analysis results; hits indicate the number of times the instrument detected the bacteria.

[0033] Figure 5B for Figure 4 The LEfSe analysis results show the abundance of Bifidobacterium in the mouse intestinal flora; hits indicate the number of times the instrument detected the bacteria.

[0034] Figure 6Schematic diagram of the intersection of physiological regulatory pathways with statistical differences in each group after PICRUSt2 analysis using a Venn diagram.

[0035] In the above figures, NC represents mice that have not been induced with antibiotics and have not been tube-fed with the probiotic composition of the present invention; Amp or Amp H2O represents mice that have been induced with antibiotics and have not been further tube-fed with the probiotic composition of the present invention; AmpLABL or Amp-LABL represents mice that have been induced with antibiotics and then further tube-fed with a low dose of the probiotic composition of the present invention; Amp LABH or Amp-LABH represents mice that have been induced with antibiotics and then further tube-fed with a high dose of the probiotic composition of the present invention. DETAILED DESCRIPTION

[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs.

[0037] The "effective amount" described herein refers to the amount of the probiotic composition required to effectively improve depression or depressive behavior caused by taking antibiotics in mammals or humans; the amount of the probiotic composition required to effectively improve the imbalance of intestinal flora and / or the decrease in species richness of intestinal flora caused by taking antibiotics in mammals or humans; the amount of the probiotic composition required to effectively increase the abundance of Bifidella and / or reduce the abundance of Staphylococcus in the intestinal flora of mammals or humans; the amount of the probiotic composition required to effectively increase the abundance of Bifidella and / or reduce the abundance of Staphylococcus in the intestinal flora of mammals or humans; the amount of the probiotic composition required to effectively increase the synthesis of flavonoids and flavonols, the synthesis of isoquinoline alkaloids, and / or the synthesis of nicotinate and nicotinamide in the intestine of mammals or humans; the amount of the probiotic composition required to effectively increase the synthesis of short-chain fatty acids in the intestine of mammals or humans. The effective amount may vary depending on the biological species or individual differences administered, but the effective amount can be determined experimentally by, for example, a dose escalation test.

[0038] The "probiotic composition" described herein refers to a lactobacillus composition comprising Lactobacillus plantarum GMNL-141, or a lactobacillus composition further comprising Lactobacillus rhamnosus GM-020 strain and / or Lactobacillus acidophilus GMNL-185 strain.

[0039] The numerical values ​​used herein are approximate values, and all experimental data are expressed within a range of 20%, preferably within a range of 10%, and most preferably within a range of 5%.

[0040] Statistical analysis was performed using Excel software. Data were expressed as mean ± standard error (SEM), and Student's t-test was used to analyze whether the sample means between the two groups were statistically significantly different (P<0.05).

[0041] The "probiotic strain (Probiotic or Probiotic bacteria)" mentioned in this article is a microorganism whose bacteria, mixed strains, extracts or metabolites have a positive effect on the host itself. It is usually derived from bacteria in the individual that are beneficial to the individual's health. It can also refer to certain microorganisms that are supplemented externally and may be beneficial to the individual.

[0042] According to the present invention, the operation procedures and parameter conditions for bacterial culture are within the scope of professional accomplishment and routine techniques of persons skilled in the art.

[0043] According to the present invention, the operating procedures and parameter conditions for tube-feeding the bacterial composition (or probiotic composition referred to herein) to experimental animals are within the professional qualities and routine technical scope of persons skilled in the art.

[0044] According to the present invention, the operating procedures and parameter conditions for the detection and analysis of the intestinal flora of experimental animals are within the scope of professional accomplishment and routine skills of people familiar with this technology.

[0045] The “richness” mentioned in this article refers to the diversity of species, for example, species richness refers to the diversity of species; while the “abundance” mentioned in this article refers to the number of a single species, for example, bacterial abundance refers to the number of bacteria.

[0046] The present invention provides a novel Lactobacillus plantarum (L. plantarum) GMNL-141 strain, which is a probiotic strain with the effect of improving depression or depressive behavior caused by antibiotics; the Lactobacillus plantarum GMNL-141 strain of the present invention is isolated from an intestinal specimen of the human small intestine; after extracting the total RNA of the Lactobacillus plantarum GMNL-141 strain of the present invention by a conventional method, the sequence of the 16S rRNA gene portion thereof is amplified by a primer pair such as sequence identification number SEQ ID NO: 1 and SEQ ID NO: 2 (the upstream primer is PAF primer, and the downstream primer is 536R primer), wherein the obtained nucleic acid fragment is shown in sequence identification number SEQ ID NO: 3; wherein, the method for extracting total RNA is well known to those having ordinary knowledge in the technical field to which the present invention belongs, and is not further described herein. Next, the nucleic acid fragment (SEQ ID NO: 3) was compared with seven 16S rRNA gene sequences of Lactobacillus plantarum in the National Center for Biotechnology Information (NCBI) gene library (GenBank numbers: NR_117813.1, NR_104573.1, NR_042394.1, NR_029133.1, NR_113338.1, NR_115605.1, and NR_136785.1), and the sequence identity was more than 99%, thus confirming that the GMNL-141 strain of the present invention is Lactobacillus plantarum (L. plantarum).

[0047] The sequence of SEQ ID NO: 1 is 5'-AGAGTTTGATCCTGGCTCAG-3' (PAF primer).

[0048] The sequence of SEQ ID NO: 2 is 5'-GTATTACCGCGGCTGCTG-3' (536R primer).

[0049] The sequence of SEQ ID NO: 3 is.

[0050] The physiological characteristics of the Lactobacillus plantarum GMNL-141 strain of the present invention are as follows: the growth temperature is 35° C. to 40° C., the growth pH is 4.0 to 7.0, and the oxygen effect is facultative anaerobic; the culturing method of the Lactobacillus plantarum GMNL-141 strain of the present invention is as follows: the GMNL-141 strain is inoculated on an agar medium (De Man, Rogosa and Sharpe, MRS) and cultured at 37° C.; the appearance characteristics of the colony of the Lactobacillus plantarum GMNL-141 strain of the present invention are as follows: the edge is complete, the average size is 3 mm x 3 mm, the colony is slightly white and large, and the surface is smooth and raised; the morphological characteristics of the Lactobacillus plantarum GMNL-141 strain of the present invention are as follows: it is rod-shaped (bacilli), has no spore formation, and has no mobility; and the Gram staining result of the Lactobacillus plantarum GMNL-141 strain of the present invention is positive.

[0051] The Lactobacillus plantarum GMNL-141 strain of the present invention was deposited at the Biological Resource Center of the National Institute of Technology and Evaluation (NITE) in Japan on August 23, 2021, and the deposit number is NITE BP-03510.

[0052] Compared with the conventional Lactobacillus plantarum CCTCC M2017767 strain, when the Lactobacillus plantarum GMNL-141 strain of the present invention was fed to mice with depression induced by antibiotics, it was observed that its efficacy in improving the depressive behavior of mice was significantly better than that of the conventional strain of the species to which it belongs.

[0053] Based on the above beneficial biological activities, the Lactobacillus plantarum GMNL-141 strain of the present invention is expected to have the potential to be used to improve depression-related symptoms. Therefore, the present invention further provides a lactobacillus composition comprising the plant lactobacillus GMNL-141 strain of the present invention, which may further comprise: Lactobacillus rhamnosus (L. rhamnosus) GM-020 strain, Lactobacillus acidophilus (L. acidophilus) GMNL-185 strain, or a combination thereof; wherein the Lactobacillus rhamnosus GM-020 strain and the Lactobacillus acidophilus GMNL-185 strain have been deposited in the China Center for Type Culture Collection (CCTCC) (430072, China-Wuhan-Wuhan University), the Lactobacillus rhamnosus GM-020 strain has a deposit number of CCTCC M203098, and a deposit date of December 18, 2003, and the Lactobacillus acidophilus GMNL-185 strain has a deposit number of CCTCC M2017764, and a deposit date of November 3, 2017. Wherein, the Lactobacillus rhamnosus (L. rhamnosus) GM-020 strain is disclosed in the patent with application number 200410030169.8 and authorization announcement number CN100396770C. The Lactobacillus acidophilus (L. acidophilus) GMNL-185 strain is disclosed in the patent with application number 201810666262.X and authorization announcement number CN110628660B. Wherein, the plant lactobacillus GMNL-141 strain, the Lactobacillus rhamnosus GM-020 strain, and the Lactobacillus acidophilus GMNL-185 strain also include their successive cultured offspring, or mutants, but still have the same strain characteristics, genome, or uses as described in the present invention.

[0054] The lactobacillus composition of the present invention can be used to prepare a pharmaceutical composition for improving depression caused by antibiotics; wherein the pharmaceutical composition can be a pharmaceutical product and can further contain a pharmaceutically acceptable excipient, carrier and / or adjuvant.

[0055] In a preferred embodiment of the present invention, the lactobacillus composition of the present invention is formulated in a pharmaceutically acceptable vehicle and prepared into a dosage form suitable for oral administration, and the pharmaceutical composition is preferably in a dosage form selected from the following groups: solution, suspension, powder, tablet, pill, syrup, lozenge, troche, chewing gum, capsule, and the like.

[0056] According to the present invention, the pharmaceutically acceptable carrier may include one or more agents selected from the following: solvent, buffer, emulsifier, suspending agent, decomposer, disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, wetting agent, lubricant, absorption delaying agent, liposome and the like. The selection and amount of these agents fall within the professional accomplishment and routine technical scope of those skilled in the art.

[0057] According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of: water, normal saline, phosphate buffered saline (PBS), an aqueous solution containing alcohol, and combinations thereof.

[0058] In another preferred embodiment of the present invention, the lactobacillus composition of the present invention can be prepared into a food product and formulated with edible materials into products including but not limited to: beverages, fermented foods, bakery products, health foods, nutritional supplements, and dietary supplements.

[0059] According to the present invention, the edible material is selected from the group consisting of water, fluid milk products, milk, concentrated milk; fermented milk, such as yogurt, sour milk, frozen yogurt, lactic acid bacteria-fermented beverages; milk powder; ice cream; cream cheeses; dry cheeses; soybean milk; fermented soybean milk; vegetable-fruit juices; juices; sports drinks; confectionery; jellies; candies; infant formulas; health foods; animal feeds; Chinese herbal medicines; and dietary supplements.

[0060] According to the present invention, the food product can be used as a food additive, which is added during the raw material preparation or during the food production process by conventional methods, and is formulated with any edible material into a food product for human and non-human animals to consume.

[0061] The following will describe in detail: the screening method of the probiotic strains constituting the probiotic composition of the present invention; and the efficacy test of the probiotic composition of the present invention in improving the individual depressive behavior caused by antibiotics, and the specific method of testing and analyzing the probiotic composition of the present invention in improving the individual depressive behavior caused by antibiotics. This is to prove that the probiotic composition of the present invention has the efficacy of improving depression caused by antibiotics, and can be used to prepare a composition with corresponding efficacy.

[0062] Example 1

[0063] Screening of probiotic strains constituting the probiotic composition of the present invention

[0064] In one embodiment of the present invention, in order to screen probiotic strains that effectively improve individual depressive behavior caused by antibiotics, mice induced by antibiotics were used as experimental animals for testing, and the reduced ability of mice to swim for survival was used as an indicator of the depressive behavior of mice caused by antibiotics. The detailed testing method is as follows: First, 7-week-old C57BL / 6 male mice were purchased, and the mice were first placed in the room for stable growth for one week before the experimental grouping began. In order to avoid differences in mice between the experimental groups, the mouse swimming survival assessment was first performed one day before the start of the experiment.

[0065] Then, the mice were divided into the following twelve groups: Groups (1) to (10) were tube-fed probiotic experimental groups (Test): antibiotics (Ampicillin was used in the present embodiment) were orally administered to the mice for two consecutive days to induce disease, and the antibiotic dose was 100 mg / kg mouse / day. Starting from the third day, low-dose single-strain probiotics were administered to the mice by tube feeding for five consecutive days. In the present embodiment, the probiotics were prepared in the form of live bacteria freeze-dried powder in 100 μL of sterile water, and the low-dose single-strain probiotics was 1.6 x 10 8cfu / mouse / day, wherein the probiotic strains in groups (1) to (10) are: (1) Lactobacillus rhamnosus (L.rhamnosus) GM-020 strain, (2) Lactobacillus reuteri (L.reuteri) CCTCC M207154 strain, (3) Lactobacillus fermentum (L.fermentum) CCTCC M204055 strain, (4) Lactobacillus plantarum (L.plantarum) GMNL-141 strain, (5) Lactobacillus acidophilus (L.acidophilus) GMNL-185 strain, (6) Lactobacillus casei (L.casei) CCTCC M2013197 strain, (7) Lactobacillus fermentum (L.fermentum) CCTCC M204055 strain, fermentum, L.fermentum), (8) Lactobacillus paracasei, L.paracasei CCTCCM2016225, (9) Lactobacillus rhamnosus, L.rhamnosus CCTCCM2017766, and (10) Lactobacillus plantarum, L.plantarum CCTCCM2017767; Group (11) was the negative control group (Sham): mice were orally given phosphate buffered saline (PBS) for two consecutive days. saline, hereinafter referred to as PBS solution), and sterile Milli-Q ultrapure water (Merck, hereinafter referred to as MQ water) was given for five consecutive days starting from the next day, for a total of six mice; and the 12th group was the positive control group (Control): antibiotics (Ampicillin was used in the embodiment of the present invention) were orally administered to mice for two consecutive days to induce disease, the dose of antibiotics was 100 mg / kg mouse / day, and sterile MQ water was given for five consecutive days starting from the next day, for a total of six mice.

[0066] Next, the swimming survival ability of mice was evaluated on the fourth day after the grouping (i.e., the twelfth day of the overall test). In order to compare and evaluate the efficacy of different groups of animals in improving individual depressive behaviors, the following formulas were used to quantify the efficacy (I) of restoring the swimming ability of mice after administration of probiotic strains from groups (1) to (10), as a reference for selecting the most effective probiotic strain:

[0067]

[0068] The results of the efficacy test of restoring the swimming survival ability of mice after administering the ten different probiotic strains to mice induced by antibiotics are shown in Table 1. It can be seen that the top three strains with the best efficacy of restoring the swimming survival ability of mice are the rhamnosus Lactobacillus GM-020 strain of test group (1), the plantarum Lactobacillus GMNL-141 strain of test group (4), and the acidophilus Lactobacillus GMNL-185 strain of test group (5), and the efficacy of these three strains is significantly better than other strains of the same species, indicating that the rhamnosus Lactobacillus GM-020 strain, the plantarum Lactobacillus GMNL-141 strain, and the acidophilus Lactobacillus GMNL-185 strain have the efficacy of improving individual depressive behavior; then, further, the top three probiotic strains with the best efficacy are mixed in a ratio of 1:1:1 to form a composite formula of the probiotic composition of the present invention, and the efficacy of the probiotic composition in improving the depressive behavior of individuals caused by antibiotics is tested by the above method. The detailed testing method will be described later.

[0069] Table 1

[0070]

[0071] Example 2

[0072] The probiotic composition of the present invention improves individual depressive behavior caused by antibiotics

[0073] In one embodiment of the present invention, in order to test the efficacy of the probiotic composition of the present invention described in Example 1 in improving the depressive behavior of individuals induced by antibiotics, the method of Example 1 was used to test mice induced by antibiotics as experimental animals, and the reduction of the nesting and swimming survival abilities of the mice was used as an indicator of the depressive behavior of the mice caused by antibiotics.

[0074] The detailed test method is as follows: First, the mice were tested for nesting and swimming survival on the day before the start of the experiment. Then, the mice were divided into (13) a low-dose test group (Amp-LABL) and (14) a high-dose test group (Amp-LABH), with five mice in each group. The mice were given antibiotics orally for two consecutive days to induce disease. The antibiotic dose was 100 mg / kg mouse / day. Starting from the third day, the mice were given a low-dose or high-dose probiotic composition by tube feeding for five consecutive days. The low-dose probiotic composition was 1.6x10 8 cfu / mouse / day, which translates to a human dose of 4x10 per day for a 60 kg adult 10 cfu, while the high-dose probiotic combination had 4.8x10 8cfu / mouse / day, which translates to a human dose of 1.2x10 per day for a 60 kg adult 11 cfu; In addition, the negative control group (NC) and the positive control group (Amp or Amp H2O) were tested in the same manner as in Example 1; wherein the composite probiotic composition of the present invention is a high bacterial count bacterial powder (1x10 11 cfu / g), and then the high bacterial count powder was diluted with sterile water to a specific concentration and then fed to mice.

[0075] Then, on the eighth day of the overall test (i.e., the day after the grouping), and the twelfth day of the overall test (i.e., the fourth day after the grouping), the mice were tested for nesting and swimming survival ability, and the results were as follows: Figure 1A and Figure 1B As shown; among them, Figure 1A It can be seen that compared with the positive control group (Amp H2O), after the use of antibiotics to induce disease and the low dose of the probiotic composition of the present invention (Amp / LABL) was fed via tube, the behavioral changes in the nesting ability of the mice were significantly improved on the twelfth day; and compared with the positive control group (Amp H2O), after the use of antibiotics to induce disease and the high dose of the probiotic composition of the present invention (Amp / LABH) was fed via tube, the behavioral changes in the nesting ability of the mice were significantly improved on the eighth day and the twelfth day, indicating that the high dose of the probiotic composition of the present invention can achieve the effect more quickly in a shorter time.

[0076] Depend on Figure 1B It can be seen that compared with the positive control group (Amp H2O), after the use of antibiotics to induce disease and feeding a low dose of the probiotic composition of the present invention (Amp / LABL) through a tube, a significant improvement in the behavioral changes in the swimming survival ability of the mice can be observed on the eighth day; and compared with the positive control group (Amp H2O), after the use of antibiotics to induce disease and feeding a high dose of the probiotic composition of the present invention (Amp / LABH) through a tube, a significant improvement in the behavioral changes in the swimming survival ability of the mice can also be observed on the eighth day.

[0077] In summary, after antibiotics induced disease, whether the mice were given a low dose or a high dose of the probiotic composition of the present invention, their behavioral changes in nesting ability and swimming survival ability were effectively improved, indicating that both a low dose and a high dose of the probiotic composition of the present invention can effectively improve the individual depressive behavior caused by antibiotics, and a high dose can achieve the effect more quickly in a shorter time.

[0078] In this example, in order to further compare and evaluate the efficacy of the compound probiotic composition of the present invention in improving the depressive behavior of an individual compared with a single probiotic strain, the formula (I) of Example 1 was used to quantify the efficacy of the low-dose and high-dose probiotic compositions in restoring the swimming ability of mice, and the following formula (II) was used to quantify the efficacy of the low-dose and high-dose probiotic compositions in restoring the nesting ability of mice:

[0079]

[0080] The quantified results are shown in Table 2, which shows that compared with the use of the Lactobacillus rhamnosus GM-020 strain of the test group (1) in Example 1, the Lactobacillus plantarum GMNL-141 strain of the test group (4), and the Lactobacillus acidophilus GMNL-185 strain of the test group (5), the use of the low-dose probiotic composition of the present invention in group (13) or the high-dose probiotic composition of the present invention in group (14) in Example 1, the effect trend of improving the nesting ability and swimming ability of mice is significantly better than that of using a single probiotic strain.

[0081] Table 2

[0082]

[0083] Example 3

[0084] The probiotic composition of the present invention improves intestinal flora to improve individual depression caused by antibiotics

[0085] In one embodiment of the present invention, in order to further understand the mechanism by which the probiotic composition of the present invention improves the depressive behavior of an individual caused by antibiotics, high-throughput next-generation sequencing (NGS) technology and bioinformatics are used to further analyze the changes in the bacterial phase of mice whose depressive behavior has improved after taking the probiotic composition of the present invention, so as to evaluate whether the probiotic composition of the present invention achieves the purpose of improving depression by regulating the bacterial phase of the individual.

[0086] In Example 2, after the experimental animals were given a low dose or a high dose of the probiotic composition of the present invention, including a negative control group and a positive control group, the intestinal tissue of each mouse in each test group was sampled, wherein the distal ileum close to the mouse cecum was cut off, and the tissue was cut into pieces and then the specimens were shaken by a homogenizer to homogenize the sampled intestinal tissue, followed by centrifugation to obtain the intestinal flora microorganisms in the supernatant, and the DNA of the intestinal flora microorganisms was extracted using the QIAmp Rapid DNA Isolation Kit (purchased from Qiagen, Germany) according to the standard operating manual. Next, the extracted DNA was tested for concentration using a micro-sample spectrophotometer (NanoDrop 2000) (the ratio of OD 260 to OD 280 must be between 1.7 and 2.2, and the DNA concentration must be greater than 50 ng / μL), and each sample was diluted to 4 to 6 ng / μL using the elution buffer (EB) included in the kit for subsequent 16S rRNA (16S ribosomal RNA) next-generation sequencing analysis to identify the species composition of the intestinal flora of each group of mice.

[0087] When performing next-generation sequencing analysis of 16S rRNA, KAPA HiFi DNA polymerase (purchased from Roche, USA) was used to amplify variable regions 3 and 4 of 16S rRNA (V3-V4), and the amplified DNA was purified using KAPA purification magnetic beads (purchased from Roche, USA). Next, the purified DNA was subjected to capillary electrophoresis (Fragment Analyzer, purchased from Advanced analytical, USA) and fluorescence spectrophotometer (Qubit 3.0, purchased from ThermoFisher, USA) to confirm the quality of the purified DNA, and then the purified DNA was subjected to a second PCR to establish a library (Nextera XT Index Kit A, purchased from Illumina, USA), and the obtained PCR product was purified again using KAPA purification magnetic beads, and the quality was confirmed by capillary electrophoresis and fluorescence spectrophotometer, and the concentration was confirmed at the same time. When the concentration of the library-labeled DNA reached 4 nM after mixing, it was mixed with 20% viral DNA (PhiX Control, purchased from Illumina, USA), and then the MiSeq v3 600cycle analysis kit was used to perform next-generation sequencing of 16S rRNA of the intestinal flora of mice in each test group.

[0088] Next, the next generation sequencing results of 16S rRNA were analyzed by bioinformatics. First, the Fastq obtained after next generation sequencing was analyzed by Qiime2 software, and DNA fragments less than 400 were removed by DaDa2, and sequence fragments with a similarity of 97% in the Greengene v13.8 database were compared to establish an operational unit table (Operational Taxonomic Unit, OTU table), in which the bacteria in the intestines of each group of mice were classified by phylum OUTs and genus OUTs, and the analysis results were made into bar graphs, as shown below. Figure 2A and 2B As shown, each column represents the average changes in the intestinal flora of multiple mice.

[0089] Depend on Figure 2A and 2B It can be seen that, compared with the negative control group that was not fed with antibiotics, feeding antibiotics to induce disease does cause significant changes in the intestinal flora of mice; and after feeding antibiotics to induce disease, feeding low or high doses of the probiotic composition of the present invention by tube can make the intestinal flora of mice grow and decline to be more similar to the intestinal flora of healthy mice in the negative control group. More specifically, in the intestinal flora of mice in the positive control group (Amp) fed with antibiotics, the abundance of Firmicutes and Staphylococcus will increase significantly, while the abundance of Bacteroidetes, Lactobacillus, and Bacteroidales (f_S24-7) will decrease significantly; in the intestinal flora of the negative control group, the mice fed with low doses of the probiotic composition of the present invention, and the mice fed with high doses of the probiotic composition of the present invention, a completely opposite distribution trend is presented. This result shows that the probiotic composition of the present invention can restore the intestinal flora changes and imbalances caused by taking antibiotics to a state close to that of a healthy individual.

[0090] Example 4

[0091] The probiotic composition of the present invention increases intestinal species richness in individuals with antibiotic-induced depression

[0092] Furthermore, some studies have pointed out that taking antibiotics may cause a decrease in the alpha diversity of intestinal flora. Therefore, in the embodiments of the present invention, in order to further evaluate whether the probiotic composition of the present invention can improve the decrease in alpha diversity caused by antibiotics, the alpha diversity of the intestinal flora of mice whose depressive behavior has been improved after taking the probiotic composition of the present invention is further analyzed; wherein alpha diversity refers to the biodiversity of a single cluster within a sample or habitat. The specific analysis method is to directly perform species diversity analysis (alphaDiversity, Shannon Diversity) on the above-mentioned operation unit table obtained by Qiime2 analysis software, and the results are as follows: Figure 3 shown.

[0093] Depend on Figure 3 It can be seen that compared with the negative control group that was not fed with antibiotics, feeding antibiotics to induce disease did cause a decrease in the diversity of intestinal bacteria in mice; and after feeding antibiotics to induce disease, feeding a low or high dose of the probiotic composition of the present invention by tube feeding can quickly restore the species diversity of the intestinal flora. This result shows that the probiotic composition of the present invention can help stabilize the flora of an individual and quickly restore intestinal health.

[0094] In addition, when exploring the diversity of individual microbiota, evolutionary branch diagrams are often used to present the analysis results of the next generation sequencing of 16S rRNA, and LEfSe analysis (Linear discriminant analysis (LDA) Effect Size) is often used to calculate the evolutionary branch diagram; LEfSe analysis is an analysis algorithm used to find high-dimensional biomarkers and screen genomic features. It can find biomarkers with statistically significant differences between groups. When applied to microbial diversity analysis, LEfSe analysis can find microbial species with significant differences in abundance between groups, and this algorithm emphasizes statistical significance and biological relevance. Therefore, in an embodiment of the present invention, the LEfSe analysis online analysis software provided by Galaxy-The Huttenhower Lab is further used to perform major microbial analysis between the intestinal flora of each group of mice, wherein it is set to determine that when the LDA Score is greater than 2, it is a meaningful core flora. The analysis results are as follows. Figure 4 shown.

[0095] exist Figure 4In the evolutionary branch diagram, the circles radiating from the inside to the outside represent the classification level from the phylum to the genus (or species), and each small circle in different classification levels represents a taxonomic group at that level. The diameters of these small circles represent the relative abundances. Then, the microbial species with significant differences between the groups were colored according to the representative colors of their original groups (i.e., the negative control group, the positive control group, the low-dose probiotic composition group of the present invention, and the low-dose probiotic composition group of the present invention). Then, the bacterial families, genera, and species with significant changes in the intestinal flora of each group of mice were sorted out in Table 3, and the abundances of Staphylococcus and Bifidobacterium, which had the most significant changes, in each group were sorted out and plotted as Figure 5A and Figure 5B ; Among them, when conducting bacterial phase analysis, the number of times the instrument detects bacteria is expressed as % hit. The higher the number of hits or the higher the hit percentage, the more total numbers of the bacteria species detected.

[0096] Table 3

[0097]

[0098] Depend on Figure 5A and Figure 5B It can be seen that in the intestinal flora of the positive control group of mice fed only with antibiotics and having depressive behavior, the abundance of Staphylococcus increased significantly compared with the intestinal flora of the other three groups, indicating that Staphylococcus is related to the occurrence of individual depressive behavior; in addition, after being fed with antibiotics to induce disease, the abundance of Bifidobacterium in the intestinal flora of mice fed with low or high doses of the probiotic composition of the present invention by tube increased relatively significantly, indicating that Bifidobacterium is related to the improvement of the probiotic composition of the present invention on the depressive behavior of individuals caused by antibiotics, and Bifidobacterium is known to be a bacterium that is beneficial to human health and has a positive effect on emotional stability.

[0099] Based on the above analysis results, it can be seen that the probiotic composition of the present invention can improve the imbalance of intestinal flora of an individual caused by antibiotics, help restore and stabilize the species diversity of intestinal flora, and increase the abundance of Bifidobacteria, thereby improving the depression of an individual caused by antibiotics.

[0100] Example 5

[0101] The probiotic composition of the present invention increases the synthesis of mood-stabilizing substances in individuals with antibiotic-induced depression

[0102] In one embodiment of the present invention, in order to understand the intestinal microorganisms regulated by the probiotic composition of the present invention, PICRUSt2 (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2) was further used to analyze the regulatory pathways involved in the intestinal microorganisms of the aforementioned groups of mice, so as to understand which physiological regulatory pathways of the individual are affected by the probiotic composition of the present invention to improve the individual depressive behavior caused by antibiotics; wherein PICRUSt2 is a tool for predicting the abundance of microbial functions based on the sequences of the marked genes, and can be applied to predict the function of 16S rRNA sequences.

[0103] First, the 16S rRNA sequencing results of the intestinal flora of each group of mice obtained in Example 3, including the negative control group, the positive control group, the low-dose probiotic composition of the present invention, and the high-dose probiotic composition of the present invention, were used to predict and analyze the physiological regulation pathways involved in intestinal microorganisms using PICRUSt2. Then, the physiological regulation pathways obtained by the prediction analysis of each group were grouped into the following groups: (1) the negative control group (NC) was compared with the positive control group (Amp), (2) the positive control group (Amp) was compared with the low-dose probiotic composition of the present invention group (Amp-LABL), and (3) the positive control group (Amp) was compared with the high-dose probiotic composition of the present invention group (Amp-LABH). The physiological regulation pathways with statistical differences were compared in pairs to find out. All analysis results were considered statistically significant when the p value was less than 0.05.

[0104] Next, the physiological regulation pathways with statistical differences found in the above three comparisons were intersected using the Venn diagram to further find physiological regulation pathways with common statistical differences in the three comparisons. The results are as follows: Figure 6 As shown, it can be seen that: the negative control group (NC) is compared with the positive control group (Amp), and the change in the intestinal flora of mice affects about 102 physiological regulation pathways; the positive control group (Amp) is compared with the low-dose probiotic composition group of the present invention (Amp-LABL), which affects about 100 physiological regulation pathways; and the positive control group (Amp) is compared with the high-dose probiotic composition group of the present invention (Amp-LABH), which affects about 81 physiological regulation pathways; among them, 49 physiological regulation pathways are physiological regulation pathways that have common statistical differences in these three comparisons.

[0105] In order to understand the physiological regulation pathways related to the probiotic composition of the present invention in improving individual depressive behavior, the 49 detailed physiological regulation pathways were summarized in Table 4 as increasing (Increase, I) or decreasing (Decrease, D) trends in the three comparisons. It can be seen that the biosynthesis of flavonoids and flavonols, isoquinoline alkaloids, The synthesis of nicotinate and nicotinamide (i.e., the amide form of vitamin B3) and the metabolism of nicotinate and nicotinamide (i.e., the amide form of vitamin B3) are all physiological regulation pathways that show a downward trend in the group taking antibiotics to induce disease, and then show an upward trend in the group fed with low or high doses of the probiotic composition of the present invention after induction of disease. In addition, past studies have shown that the substances synthesized by these three physiological regulation pathways are all substances that can increase mood stability and have the effect of improving individual depression. This result indicates that the probiotic composition of the present invention can restore the physiological regulation pathways that are decreased due to antibiotics to increase the synthesis of mood-stabilizing substances, and has the beneficial effect of improving the depressive behavior of individuals caused by antibiotics.

[0106] Table 4

[0107]

[0108]

[0109] In addition, it can be seen from Table 4 that in the group taking antibiotics to induce disease, the incidence of Staphylococcus aureus infection showed an upward trend, while in the group fed with the probiotic composition of the present invention after inducing disease, the incidence of Staphylococcus aureus infection showed a downward trend. In past studies, it was also found that Staphylococcus aureus infection would cause individual bacterial disorder and affect the synthesis of short-chain fatty acids (SCFA); this result shows that the probiotic composition of the present invention can slow down the increase of Staphylococcus aureus infection caused by antibiotics, so as to produce a beneficial effect of improving the depressive behavior of individuals caused by antibiotics.

[0110] Example 6

[0111] The probiotic composition of the present invention increases the synthesis of short-chain fatty acids in individuals with antibiotic-induced depression

[0112] Since past studies have shown that short-chain fatty acids secreted by intestinal microorganisms of an individual help stabilize the individual's mood, cognition, and behavior, thereby effectively reducing the occurrence of depression in the individual, in one embodiment of the present invention, it is further tested whether the probiotic composition of the present invention can increase the synthesis of short-chain fatty acids in the intestinal tract of an individual, so as to produce the effect of improving depression in an individual caused by antibiotics.

[0113] After the experimental animals were given a low dose or a high dose of the probiotic composition of the present invention in Example 2, including a negative control group and a positive control group, the feces of each mouse in each test group were sampled, and the feces taken from different mice in the same group were mixed in equal amounts into a single tube analysis sample, and then the composition of short-chain fatty acids in the feces of each tube analysis sample was analyzed using a gas chromatography mass spectrometer (GC / MS), and the results were expressed in units of μmol / g; wherein the short-chain fatty acids mainly include acetic acid, propionic acid, and butyric acid.

[0114] The detailed sample processing and detection methods are briefly described as follows: First, take a total of 0.5 g of fecal sample from each test group of mice and place it in a 15 mL centrifuge tube. Then add 5 mL of pure water to dissolve it and shake it for 2 minutes. Then, filter the supernatant after centrifugation (7000 rpm, 5 minutes) (0.45 μm) and put the solution into a new 15 mL centrifuge tube, which is the analysis sample of each test group. Next, take 2 mL of the prepared analytical sample into a new 15 mL centrifuge tube, add 0.2 mL of 50% sulfuric acid solution, then add 2 mL of ether, shake 30 times and centrifuge (>10,000 rpm, 5 minutes), then place in a refrigerator (4°C) for 30 minutes, take the upper ether solution layer and analyze it by gas chromatography mass spectrometry (GC / MS). The conditions of gas chromatography mass spectrometry are as follows: use FFAP elastic quartz capillary column (30m×0.25mm×0.25μm); chromatographic column temperature program: 100°C (1 minute), 5°C / min to 150°C (5 minutes); carrier gas: high-purity nitrogen, purity ≧99.999%; carrier gas flow rate 2mL / min; injection port temperature: 270°C; injection mode: splitless injection, injection volume 2.0μL; detector temperature (FID): 280°C. Finally, the standard was used as a comparison benchmark to convert the content of the six short-chain fatty acids in each gram of fecal analysis sample and expressed in units of μmole / g.

[0115] The measurement results of the short-chain fatty acid content in the feces of each group of mice are shown in Table 5. As can be seen from Table 5, compared with the negative control group that was not fed with antibiotics, the acetic acid content in the feces of mice fed with antibiotics to induce disease will be slightly reduced, while the propionic acid and butyric acid contents will be significantly reduced. If after feeding antibiotics to induce disease, the low or high dose of the probiotic composition of the present invention is fed by tube, the acetic acid, propionic acid, and butyric acid contents in the feces of mice will all increase significantly. These results show that the reduction of short-chain fatty acids in the intestine of an individual will indeed lead to the occurrence of depressive behavior in the individual, and the probiotic composition of the present invention can improve the depression of the individual caused by antibiotics by increasing the synthesis of short-chain fatty acids in the intestine of the individual.

[0116] Table 5

[0117]

[0118] In summary, the present invention screened the Lactobacillus rhamnosus GM-020 strain, the Lactobacillus plantarum GMNL-141 strain, and the Lactobacillus acidophilus GMNL-185 strain with the best efficacy in improving depression caused by antibiotics through animal experiments, and prepared the three probiotic strains into a composite formula of the probiotic composition of the present invention. It is confirmed through animal experiments that the probiotic composition of the present invention, whether at a low dose or a high dose, can effectively improve the individual depressive behavior caused by antibiotics, and its efficacy is better than that of using a single probiotic strain.

[0119] Furthermore, the probiotic composition of the present invention can improve the imbalance of individual intestinal flora caused by antibiotics, and help stabilize and enhance the species richness of the intestinal flora, especially increase the abundance of Bifidobacterium and reduce the abundance of Staphylococcus, so that the individual intestinal flora can quickly return to a state close to that of a healthy individual. In addition, the probiotic composition of the present invention can regulate the intestinal flora of an individual to increase the biosynthesis of flavonoids and flavonols that help stabilize mood, the biosynthesis of isoquinoline alkaloids, and the metabolism of nicotinate and nicotinamide in the intestine, and can also directly increase the synthesis of short-chain fatty acids in the intestine, thereby improving depression or depressive behavior caused by taking antibiotics in an individual.

[0120]

Explanation of symbols

[0121] none.

[0122]

Biological Material Deposit

[0123] 1.The Lactobacillus plantarum GMNL-141 strain was deposited at the Bioresource Center of the National Institute of Technology and Evaluation, Japan; August 23, 2021; the deposit number is NITE BP-03510.

[0124] 2. Lactobacillus rhamnosus GM-020 strain was deposited in China Center for Type Culture Collection on December 18, 2003; the deposit number is CCTCC M203098.

[0125] 3. Lactobacillus acidophilus GMNL-185 strain was deposited in China Center for Type Culture Collection on November 3, 2017; the deposit number is CCTCC M2017764.

Claims

1. A Lactobacillus plantarum (L. plantarum) GMNL-141 strain, characterized in that: The deposit number of the GMNL-141 strain is NITE BP-03510.

2. A lactobacillus composition for improving depression caused by the antibiotic ampicillin, characterized in that: The method comprises the Lactobacillus plantarum GMNL-141 strain as claimed in claim 1.

3. The lactobacillus composition according to claim 2, characterized in that The lactobacillus composition further comprises Lactobacillus rhamnosus (L.rhamnosus) GM-020 strain, Lactobacillus acidophilus (L.acidophilus) GMNL-185 strain, or a combination thereof; wherein the preservation number of the Lactobacillus rhamnosus GM-020 strain is CCTCC M203098, and the preservation number of the Lactobacillus acidophilus GMNL-185 strain is CCTCC M2017764.

4. The lactobacillus composition according to claim 3, characterized in that The Lactobacillus plantarum GMNL-141 strain, the Lactobacillus rhamnosus GM-020 strain, and the Lactobacillus acidophilus GMNL-185 strain are mixed in an equal bacterial count ratio of 1:1:

1.

5. The lactobacillus composition according to any one of claims 2 to 4, characterized in that The Lactobacillus plantarum GMNL-141 strain, the Lactobacillus rhamnosus GM-020 strain, and the Lactobacillus acidophilus GMNL-185 strain are live bacteria or dead bacteria.

6. A use of a lactobacillus composition for preparing a pharmaceutical composition for improving depression caused by the antibiotic ampicillin, characterized in that: The lactobacillus composition is the lactobacillus composition according to any one of claims 2 to 4.

7. The use according to claim 6, characterized in that The antibiotic is Ampicillin.

8. The use according to claim 6, characterized in that The Lactobacillus composition improves the imbalance of intestinal flora and / or the decrease in species richness of intestinal flora caused by antibiotics.

9. The use according to claim 6, characterized in that: The Lactobacillus composition increases the abundance of Bifidobacterium and / or decreases the abundance of Staphylococcus in the intestinal flora.

10. The use according to claim 6, characterized in that The lactobacillus composition increases the synthesis of flavonone and flavonol, the synthesis of isoquinoline alkaloid, and / or the synthesis of nicotinate and nicotinamide in the intestine.

11. The use according to claim 6, characterized in that: The lactobacillus composition increases the synthesis of short-chain fatty acids (SCFA) in the intestine.

12. The use according to claim 6, characterized in that The effective amount of the lactobacillus composition is at least 6.7 x 10 8 cfu / kg.

13. The use according to claim 6, characterized in that The pharmaceutical composition is a pharmaceutical product.

14. The use according to claim 6, characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable excipient, carrier, and / or adjuvant.

15. The use according to claim 6, characterized in that The pharmaceutical composition is in the form of a solution, a suspension, a semi-solid preparation, and / or a solid preparation.

16. The use according to claim 6, characterized in that The dosage form of the pharmaceutical composition is a gelatin capsule, a soft capsule, a tablet, a pill, a syrup, a tablet, a chewing gum, and / or a freeze-dried powder preparation.

17. The use according to claim 6, characterized in that The dosage form of the pharmaceutical composition is a buccal tablet.